FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Werner Kalow

Research Profile

Chemicals & Drugs

Occupations

Pharmacogenetics

Anatomy

Concepts & Ideas

Physiology

Phenomena

Oxidation-Reduction

Procedures

High Pressure Liquid Chromatography

Co-author Network

Publications

TOP 3
Werner Kalow
The relation of plasma cholinesterases to response to clinical doses of succinylcholine.
Eleni Aklillu; Werner Kalow; Laszlo Endrenyi; Patricia Harper; Jun Miura; Vural Ozdemir
CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine.
Vural Ozdemir; Leif Bertilsson; Jun Miura; Erin Carpenter; Christopher Reist; Patricia Harper; Jolanta Widén; Jan-Olof Svensson; Lawrence J Albers; James L Kennedy; Laszlo Endrenyi; Werner Kalow
CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Werner Kalow (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2008: Werner Kalow
The relation of plasma cholinesterases to response to clinical doses of succinylcholine.
Canadian journal of anaesthesia = Journal canadien d'anesthésie 2008;55(12):860-68.
2007: Eleni Aklillu; Werner Kalow; Laszlo Endrenyi; Patricia Harper; Jun Miura; Vural Ozdemir
CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine.
Pharmacogenetics and genomics 2007;17(11):989-93.
2007: Vural Ozdemir; Leif Bertilsson; Jun Miura; Erin Carpenter; Christopher Reist; Patricia Harper; Jolanta Widén; Jan-Olof Svensson; Lawrence J Albers; James L Kennedy; Laszlo Endrenyi; Werner Kalow
CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6-serotonin-dopamine crosstalk revisited.
Pharmacogenetics and genomics 2007;17(5):339-47.
2007: Werner Kalow
Personalized medicine: some thoughts.
McGill journal of medicine : MJM : an international forum for the advancement of medical sciences by students 2007;10(1):58.
2006: Werner Kalow
Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine.
The pharmacogenomics journal 2006;6(3):162-5.
2005: Werner Kalow
A pharmacogeneticist's look at drug effects and the drug development process: an overview.
Expert opinion on pharmacotherapy 2005;6(8):1299-303.
2005: Werner Kalow
Pharmacogenomics: historical perspective and current status.
Methods in molecular biology (Clifton, N.J.) 2005;311():3-15.
2004: D M Grant; Bing-Kou Tang; Werner Kalow
A simple test for acetylator phenotype using caffeine. 1984.
British journal of clinical pharmacology 2004;58(7):S788-93; discussion S794-5.
2004: Werner Kalow
Human pharmacogenomics: the development of a science.
Human genomics 2004;1(5):375-80.
2004: Werner Kalow
Atypical plasma cholinesterase. A personal discovery story: a tale of three cities.
Canadian journal of anaesthesia = Journal canadien d'anesthésie 2004;51(3):206-11.
2003: Werner Kalow
Medical practice, race, and drug use.
Clinical pharmacology and therapeutics 2003;73(1):132-4.
2002: Sherwin K B Sy; James A Johnston; Christopher F Class; Eve A Roberts; Werner Kalow; Bing-Kou Tang
Mulitvariate cluster analysis of a human hepatic cytochrome P450 database.
European journal of clinical pharmacology 2002;58(8):559-62.
2002: Werner Kalow
Pharmacogenetics and personalised medicine.
Fundamental & clinical pharmacology 2002;16(5):337-42.
2002: Sherwin K B Sy; Antonio Ciaccia; Wei Li; Eve A Roberts; Allan B Okey; Werner Kalow; Bing-Kou Tang
Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression.
European journal of clinical pharmacology 2002;58(5):357-65.
2002: Werner Kalow
Both populations and individuals are evolutionary targets: pharmacogenomic and cultural indicators.
The pharmacogenomics journal 2002;2(1):12-4.
2001: Vural Ozdemir; Werner Kalow; Allan B Okey; Maria S M Lam; Lawrence J Albers; Christopher Reist; J Fourie; P Posner; E J Collins; R Roy
Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine.
Journal of clinical psychopharmacology 2001;21(6):603-7.
2001: Sherwin K B Sy; Bing-Kou Tang; A Pastrakuljic; Eve A Roberts; Werner Kalow
Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine.
European journal of clinical pharmacology 2001;57(5):377-86.
2001: Vural Ozdemir; Werner Kalow; P Posner; E J Collins; James L Kennedy; Bing-Kou Tang; Lawrence J Albers; Christopher Reist; R Roy; W Walkes; P Afra
CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentrationin patients with schizophrenia.
Journal of clinical psychopharmacology 2001;21(4):398-407.
2001: Werner Kalow
Pharmacogenetics, pharmacogenomics, and pharmacobiology.
Clinical pharmacology and therapeutics 2001;70(1):1-4.
2001: Werner Kalow
Pharmacogenetics in perspective.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(4 Pt 2):468-70.
2001: Werner Kalow; Vural Ozdemir; László Tóthfalusi
Multigenic traits and risk assessment in pharmacology: a population approach.
The pharmacogenomics journal 2001;1(4):234-6.
2001: Vural Ozdemir; Neil H Shear; Werner Kalow
What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects?
Drug safety : an international journal of medical toxicology and drug experience 2001;24(2):75-85.
2001: Werner Kalow
Perspectives in pharmacogenetics.
Archives of pathology & laboratory medicine 2001;125(1):77-80.
2000: Vural Ozdemir; Werner Kalow; Bing-Kou Tang; A D Paterson; S E Walker; Laszlo Endrenyi; Angela D M Kashuba
Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method.
Pharmacogenetics 2000;10(5):373-88.
2000: Vincenzo S Basile; Vural Ozdemir; Mario Masellis; M L Walker; Herbert Y Meltzer; Jeffrey A Lieberman; Steven G Potkin; Gustavo Alva; Werner Kalow; Fabio Macciardi; James L Kennedy
A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia.
Molecular psychiatry 2000;5(4):410-7.
1999: Werner Kalow; Vural Ozdemir; Bing-Kou Tang; László Tóthfalusi; Laszlo Endrenyi
The science of pharmacological variability: an essay.
Clinical pharmacology and therapeutics 1999;66(5):445-7.
1999: Vural Ozdemir; R F Tyndale; Kenton Reed; Nathan Herrmann; Edward M Sellers; Werner Kalow; Claudio A Naranjo
Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers.
Journal of clinical psychopharmacology 1999;19(5):472-5.
1999: Werner Kalow; Laszlo Endrenyi; B Tang
Repeat administration of drugs as a means to assess the genetic component in pharmacological variability.
Pharmacology 1999;58(6):281-4.
1998: Werner Kalow; Bing-Kou Tang; Laszlo Endrenyi
Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research.
Pharmacogenetics 1998;8(4):283-9.
1998: Mario Masellis; Vincenzo S Basile; Herbert Y Meltzer; Jeffrey A Lieberman; Serge Sevy; Fabio Macciardi; P Cola; A Howard; F Badri; M M Nöthen; Werner Kalow; James L Kennedy
Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1998;19(2):123-32.
1998: Vural Ozdemir; Claudio A Naranjo; RW Shulman; Nathan Herrmann; Edward M Sellers; Kenton Reed; Werner Kalow
Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo.
Journal of clinical psychopharmacology 1998;18(3):198-207.
1998: Vural Ozdemir; Claudio A Naranjo; Nathan Herrmann; RW Shulman; Edward M Sellers; Kenton Reed; Werner Kalow
The extent and determinants of changes in CYP2D6 and CYP1A2 activities with therapeutic doses of sertraline.
Journal of clinical psychopharmacology 1998;18(1):55-61.
1997: Werner Kalow
Pharmacogenetics in biological perspective.
Pharmacological reviews 1997;49(4):369-79.
1997: Vural Ozdemir; Claudio A Naranjo; Nathan Herrmann; Kenton Reed; Edward M Sellers; Werner Kalow
Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo.
Clinical pharmacology and therapeutics 1997;62(3):334-47.
1997: D Wu; SV Otton; Tadanobu Inaba; Werner Kalow; Edward M Sellers
Interactions of amphetamine analogs with human liver CYP2D6.
Biochemical pharmacology 1997;53(11):1605-12.
1997: A Pastrakuljic; Bing-Kou Tang; Eve A Roberts; Werner Kalow
Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole.
Biochemical pharmacology 1997;53(4):531-8.
1997: P Rady-Pentek; R Mueller; Bing-Kou Tang; Werner Kalow
Interindividual variation in the enzymatic 15-keto-reduction of 13,14-dihydro-15-keto-prostaglandin E1 in human liver and in human erythrocytes.
European journal of clinical pharmacology 1997;52(2):147-53.
1996: G Appanna; Bing-Kou Tang; R Mller; Werner Kalow
A sensitive method for determination of cytochrome P4502D6 activity in vitro using bupranolol as substrate.
Drug metabolism and disposition: the biological fate of chemicals 1996;24(3):303-6.
1996: Bing-Kou Tang; Werner Kalow
Assays for CYP1A2 by testing in vivo metabolism of caffeine in humans.
Methods in enzymology 1996;272():124-31.
1995: M Patel; Bing-Kou Tang; Denis M Grant; Werner Kalow
Interindividual variability in the glucuronidation of (S) oxazepam contrasted with that of (R) oxazepam.
Pharmacogenetics 1995;5(5):287-97.
1995: D Wu; SV Otton; Werner Kalow; Edward M Sellers
Effects of route of administration on dextromethorphan pharmacokinetics and behavioral response in the rat.
The Journal of pharmacology and experimental therapeutics 1995;274(3):1431-7.
1995: M Schadel; D Wu; SV Otton; Werner Kalow; Edward M Sellers
Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition.
Journal of clinical psychopharmacology 1995;15(4):263-9.
1995: Werner Kalow
Life of a pharmacologist or the rich life of a poor metabolizer.
Pharmacology & toxicology 1995;76(4):221-7.
1995: M Patel; Bing-Kou Tang; Werner Kalow
(S)oxazepam glucuronidation is inhibited by ketoprofen and other substrates of UGT2B7.
Pharmacogenetics 1995;5(1):43-9.
1995: Bing-Kou Tang; Werner Kalow
Variable activation of lovastatin by hydrolytic enzymes in human plasma and liver. 4.
European journal of clinical pharmacology 1995;47(5):449-51.
1994: Bing-Kou Tang; Y Zhou; D Kadar; Werner Kalow
Caffeine as a probe for CYP1A2 activity: potential influence of renal factors on urinary phenotypic trait measurements.
Pharmacogenetics 1994;4(3):117-24.
1993: Werner Kalow
Pharmacogenetics: its biologic roots and the medical challenge.
Clinical pharmacology and therapeutics 1993;54(3):235-41.
1993: D Wu; SV Otton; P Morrow; T Inaba; Werner Kalow; Edward M Sellers
Human hepatic cytochrome P450 2D6-like activity in nonhuman primates: catalytic characterization in vitro.
The Journal of pharmacology and experimental therapeutics 1993;266(2):715-9.
1993: Werner Kalow; Bing-Kou Tang
The use of caffeine for enzyme assays: a critical appraisal.
Clinical pharmacology and therapeutics 1993;53(5):503-14.
1993: JM Wong; Werner Kalow; D Kadar; Y Takamatsu; T Inaba
Carbonyl (phenone) reductase in human liver: inter-individual variability.
Pharmacogenetics 1993;3(2):110-5.
1993: D Wu; SV Otton; Beth A Sproule; Usoa E Busto; T Inaba; Werner Kalow; Edward M Sellers
Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.
British journal of clinical pharmacology 1993;35(1):30-4.
1993: J Pressacco; R Muller; Werner Kalow
Interactions of bupranolol with the polymorphic debrisoquine/sparteine monooxygenase (CYP2D6).
European journal of clinical pharmacology 1993;45(3):261-4.
1992: Timothy Beischlag; Werner Kalow; W A Mahon; T Inaba
Diazepam metabolism by rat and human liver in vitro: inhibition by mephenytoin.
Xenobiotica; the fate of foreign compounds in biological systems 1992;22(5):559-67.
1992: JM Wong; W A Mahon; Werner Kalow; T Inaba
Carbonyl (phenone) reductase in human liver: structure-activity relationship among substrates.
Drug metabolism and disposition: the biological fate of chemicals 1992;20(3):465-6.
1992: L Gu; F J Gonzalez; Werner Kalow; Bing-Kou Tang
Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1.
Pharmacogenetics 1992;2(2):73-7.
1992: M Patel; Bing-Kou Tang; Werner Kalow
Variability of acetaminophen metabolism in Caucasians and Orientals.
Pharmacogenetics 1992;2(1):38-45.
1992: SV Otton; Rachel F Tyndale; D Wu; T Inaba; Werner Kalow; Edward M Sellers
Catalytic and immunologic similarities between monkey and human liver cytochrome P-450db1 (human cytochrome P-450 2D6).
Drug metabolism and disposition: the biological fate of chemicals 1992;20(1):1-5.
1991: Werner Kalow; S Sharer; B Britt
Pharmacogenetics of caffeine and caffeine-halothane contractures in biopsies of human skeletal muscle.
Pharmacogenetics 1991;1(3):126-35.
1991: Werner Kalow; Bing-Kou Tang
Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities.
Clinical pharmacology and therapeutics 1991;50(5 Pt 1):508-19.
1991: Rachel F Tyndale; T Aoyama; F Broly; T Matsunaga; T Inaba; Werner Kalow; H V Gelboin; U A Meyer; F J Gonzalez
Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype.
Pharmacogenetics 1991;1(1):26-32.
1991: Rachel F Tyndale; Roger K Sunahara; T Inaba; Werner Kalow; F J Gonzalez; Hyman B Niznik
Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6.
Molecular pharmacology 1991;40(1):63-8.
1991: Bing-Kou Tang; D Kadar; L Qian; J Iriah; J Yip; Werner Kalow
Caffeine as a metabolic probe: validation of its use for acetylator phenotyping.
Clinical pharmacology and therapeutics 1991;49(6):648-57.
1991: Rachel F Tyndale; Werner Kalow; T Inaba
Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase).
British journal of clinical pharmacology 1991;31(6):655-60.
1991: Werner Kalow; Bing-Kou Tang
Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking.
Clinical pharmacology and therapeutics 1991;49(1):44-8.
1990: Rachel F Tyndale; F J Gonzalez; James P Hardwick; Werner Kalow; T Inaba
Sparteine metabolism capacity in human liver: structural variants of human P450IID6 as assessed by immunochemistry.
Pharmacology & toxicology 1990;67(1):14-8.
1990: Hyman B Niznik; Rachel F Tyndale; F R Sallee; F J Gonzalez; James P Hardwick; T Inaba; Werner Kalow
The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins.
Archives of biochemistry and biophysics 1990;276(2):424-32.
1989: T Inaba; Werner Kalow; T Someya; S Takahashi; S W Cheung; S W Tang
Haloperidol reduction can be assayed in human red blood cells.
Canadian journal of physiology and pharmacology 1989;67(11):1468-9.
1989: J P Kassam; Bing-Kou Tang; D Kadar; Werner Kalow
In vitro studies of human liver alcohol dehydrogenase variants using a variety of substrates.
Drug metabolism and disposition: the biological fate of chemicals 1989;17(5):567-72.
1989: Rachel F Tyndale; T Inaba; Werner Kalow
Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine monooxygenase (P45OIID 1) in vitro.
Drug metabolism and disposition: the biological fate of chemicals 1989;17(3):334-40.
1988: T Inaba; A Tait; M Nakano; W A Mahon; Werner Kalow
Metabolism of diazepam in vitro by human liver. Independent variability of N-demethylation and C3-hydroxylation.
Drug metabolism and disposition: the biological fate of chemicals 1988;16(4):605-8.
1987: Bing-Kou Tang; D Kadar; Werner Kalow
An alternative test for acetylator phenotyping with caffeine.
Clinical pharmacology and therapeutics 1987;42(5):509-13.
1985: G Carro-Ciampi; M Jurima; D Kadar; Bing-Kou Tang; Werner Kalow
N-Glucosidation of amobarbital in the cat.
Canadian journal of physiology and pharmacology 1985;63(10):1263-6.
1985: M Jurima; T Inaba; D Kadar; Werner Kalow
Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians.
British journal of clinical pharmacology 1985;19(4):483-7.
1983: Bing-Kou Tang; Werner Kalow; T Inaba; D Kadar
Variation in amobarbital metabolism: evaluation of a simplified population study.
Clinical pharmacology and therapeutics 1983;34(2):202-6.
1981: G Carro-Ciampi; D Kadar; Werner Kalow
Distribution of serum paraoxon hydrolyzing activities in a Canadian population.
Canadian journal of physiology and pharmacology 1981;59(8):904-7.
1980: B A Britt; L Endrenyi; W Frodis; E Scott; Werner Kalow
Comparison of effects of several inhalation anaesthetics on caffeine-induced contractures of normal and malignant hyperthermic skeletal muscle.
Canadian Anaesthetists' Society journal 1980;27(1):12-5.